Patents by Inventor Jeremy Besnard

Jeremy Besnard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250084090
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Application
    Filed: November 18, 2024
    Publication date: March 13, 2025
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Yohei IKUMA, Junya IKEDA, Satoshi ADACHI, Harunobu MITSUNUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
  • Patent number: 12180213
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: December 31, 2024
    Assignee: SUMITOMO PHARMA CO. LTD.
    Inventors: Hidefumi Yoshinaga, Yohei Ikuma, Junya Ikeda, Satoshi Adachi, Harunobu Mitsunuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
  • Publication number: 20240262821
    Abstract: Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of PKC-theta. Such compounds are represented by Formula I, wherein the variables are defined herein.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 8, 2024
    Applicant: Exscientia Al Limited
    Inventors: Peter Ray, Anthony Bradley, Simon Richards, Catarina Santos, Jeremy Besnard, Jérôme Meneyrol, Virginie Suchaud
  • Publication number: 20240239794
    Abstract: Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of PKC-theta. Such compounds are represented by Formula I, wherein the variables are defined herein.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 18, 2024
    Applicant: Exscientia AI Limited
    Inventors: Peter Ray, Anthony Bradley, Simon Richards, Catarina Santos, Jeremy Besnard, Jérôme Meneyrol, Virginie Suchaud
  • Publication number: 20230399308
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 14, 2023
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Hiro UEMACHI, Tomomi OHNO, Jeremy BESNARD
  • Patent number: 11780820
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: October 10, 2023
    Assignee: SUMITOMO PHARMA CO., LTD.
    Inventors: Hidefumi Yoshinaga, Hiro Uemachi, Tomomi Ohno, Jeremy Besnard
  • Publication number: 20230008875
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Application
    Filed: August 17, 2022
    Publication date: January 12, 2023
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Yohei IKUMA, Junya IKEDA, Satoshi ADACHI, Harunobu MITSUNUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
  • Patent number: 11466007
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: October 11, 2022
    Assignee: SUMITOMO PHARMA CO., LTD.
    Inventors: Hidefumi Yoshinaga, Yohei Ikuma, Junya Ikeda, Satoshi Adachi, Harunobu Mitsunuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
  • Publication number: 20220213079
    Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.
    Type: Application
    Filed: December 23, 2020
    Publication date: July 7, 2022
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Yuki FUJII, Masayuki SAKUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
  • Patent number: 11339151
    Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: May 24, 2022
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Yuki Fujii, Masayuki Sakuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
  • Publication number: 20220073506
    Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 10, 2022
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Yuki FUJII, Masayuki SAKUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
  • Publication number: 20210332025
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Application
    Filed: April 23, 2021
    Publication date: October 28, 2021
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Hiro UEMACHI, Tomomi OHNO, Jeremy BESNARD
  • Patent number: 11014905
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: May 25, 2021
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hidefumi Yoshinaga, Hiro Uemachi, Tomomi Ohno, Jeremy Besnard
  • Patent number: 10800755
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: October 13, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hidefumi Yoshinaga, Hiro Uemachi, Tomomi Ohno, Jeremy Besnard
  • Patent number: 10745401
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: August 18, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hidefumi Yoshinaga, Yohei Ikuma, Junya Ikeda, Satoshi Adachi, Harunobu Mitsunuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
  • Publication number: 20200255432
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Application
    Filed: July 22, 2019
    Publication date: August 13, 2020
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Yohei IKUMA, Junya IKEDA, Satoshi ADACHI, Harunobu MITSUNUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
  • Publication number: 20200239432
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Application
    Filed: March 24, 2020
    Publication date: July 30, 2020
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Hiro UEMACHI, Tomomi OHNO, Jeremy BESNARD
  • Publication number: 20200172543
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Application
    Filed: February 10, 2020
    Publication date: June 4, 2020
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Yohei IKUMA, Junya IKEDA, Satoshi ADACHI, Harunobu MITSUNUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
  • Publication number: 20200039952
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Application
    Filed: March 12, 2018
    Publication date: February 6, 2020
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Hiro UEMACHI, Tomomi OHNO, Jeremy BESNARD
  • Patent number: 9079895
    Abstract: The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, m and n are as defined in the specification. The compounds are antagonists, reverse agonists or agonists of G-protein coupled receptors, such as dopamine D4 and 5HT1a. The inventions also relates to pharmaceutical compositions comprising the compounds and methods involving the compounds and compositions. The compounds and compositions of the invention may in particular be used in the treatment of diseases and disorders, such as neurological and neurodegenerative diseases; or as lead compounds for the design and selection of further therapeutic compounds.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 14, 2015
    Assignee: University of Dundee
    Inventors: Jeremy Besnard, Andrew Lee Hopkins, Ian Gilbert, Gian Filippo Ruda, Keren Abecassis